News - Boehringer Ingelheim, Gilead Sciences


Popular Filters

Gilead gains FDA priority review for hep C candidate sofosbuvir; new data on Boehringer's faldaprevir


US biotech firm Gilead Sciences (Nasdaq: GILD) revealed on Friday (June 7) that the US Food and Drug…

Anti-viralsAsia-PacificBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesNorth AmericaPharmaceuticalRegulationResearchsofosbuvir

Boehringer license novel HIV non-catalytic integrase inhibitors to Gilead


Two of the big names in HIV/AIDS drug research and marketing, the USA’s Gilead Sciences (Nasdaq:…

Anti-viralsBoehringer IngelheimGilead SciencesLicensingPharmaceutical

AIDS drugmakers’ charity programs fail patients, yet provide millions in tax breaks to industry, AHF accuses, but applauds Boehringer


The USA-based AIDS Healthcare Foundation (AHF) is, in its own words, “blowing the whistle”…

Boehringer IngelheimFinancialGilead SciencesNorth AmericaPharmaceuticalPricing

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top